PeptiDream Announces FDA Approval of IND Applications for Phase 1 Clinical Trials of 225Ac-PD-32766 and 64Cu-PD-32766 in Patients with Kidney Cancer（PeptiDream Inc.）

Approval of Clinical Research Protocol for 64Cu-PD-29875, a Claudin 18.2-Targeting Radiopharmaceutical, in Patients with Gastric Cancer（PeptiDream Inc.）

R&D Briefing Materials (December 5, 2025)（PeptiDream Inc.）

PeptiDream Submits IND Applications for Phase 1 Clinical Trials of 225Ac-PD-32766 and 64Cu-PD-32766 in Patients with Kidney Cancer（PeptiDream Inc.）

Upcoming Conference Presentation at RSNA2025